Contemporary role of prostate cancer antigen 3 in the management of prostate cancer

European Urology

Volumn 60, Issue 5, 2011, Pages 1045-1054

  Auprich, Marco ^a   Bjartell, Anders ^b   Chun, Felix K H ^c   De La Taille, Alexandre ^d   Freedland, Stephen J ^e   Haese, Alexander ^c   Schalken, Jack ^f   Stenzl, Arnulf ^g   Tombal, Bertrand ^h   Van Der Poel, Henk ⁱ  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d HENRI MONDOR HOSPITAL   (France)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^g UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^h CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

ⁱ NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

PCA3; Prostate biopsy; Prostate cancer detection; Staging; Targeted therapy

Indexed keywords

ANDROSTANOLONE; DUTASTERIDE; GOLGI MEMBRANE PROTEIN 1; INTERLEUKIN 24; MESSENGER RNA; ONCOLYTIC VIRUS; PROSTATE CANCER ANTIGEN 3; PROSTATE SPECIFIC ANTIGEN; SERINE PROTEINASE INHIBITOR; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE; TUMOR ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADVANCED CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER DIAGNOSIS; CANCER GENE THERAPY; CANCER GRADING; CANCER GROWTH; CANCER RISK; CANCER SCREENING; CANCER STAGING; CHROMOSOME 9Q; DIAGNOSTIC ACCURACY; DRUG TARGETING; EARLY DIAGNOSIS; FOLLOW UP; GENE LOCATION; GENE OVEREXPRESSION; HUMAN; MEDLINE; NOMOGRAM; NONHUMAN; ONCOLYTIC VIROTHERAPY; PATIENT COUNSELING; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SEX HORMONE DETERMINATION; SUICIDE GENE THERAPY; SYSTEMATIC REVIEW; TUMOR BIOPSY; TUMOR GENE; TUMOR VOLUME; URINALYSIS;

ANTIGENS, NEOPLASM; BIOPSY; DECISION SUPPORT TECHNIQUES; EARLY DETECTION OF CANCER; EVIDENCE-BASED MEDICINE; HUMANS; MALE; NEOPLASM STAGING; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 80053315206     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2011.08.003     Document Type: Review

References (56)

1. M.J. Bussemakers, A. van Bokhoven, and G.W. Verhaegh DD3: a new prostate-specific gene, highly overexpressed in prostate cancer Cancer Res 59 1999 5975 5979 (Pubitemid 30004960)
2. J.B. de Kok, G.W. Verhaegh, and R.W. Roelofs DD3(PCA3), a very sensitive and specific marker to detect prostate tumors Cancer Res 62 2002 2695 2698 (Pubitemid 34462754)
3. PCA3-based molecular urine analysis for the diagnosis of prostate cancer Eur Urol 44 2003 8 16 discussion 15-6 (Pubitemid 36741368)
4. K.A. Landers, M.J. Burger, and M.A. Tebay Use of multiple biomarkers for a molecular diagnosis of prostate cancer Int J Cancer 114 2005 950 956
5. U. Schmidt, S. Fuessel, and R. Koch Quantitative multi-gene expression profiling of primary prostate cancer Prostate 66 2006 1521 1534 (Pubitemid 44465817)
6. H. Bialkowska-Hobrzanska, D.K. Driman, R. Fletcher, V. Harry, and H. Razvi Expression of human telomerase reverse transcriptase, survivin, DD3 and PCGEM1 messenger RNA in archival prostate carcinoma tissue Can J Urol 13 2006 2967 2974
7. I. Popa, Y. Fradet, G. Beaudry, H. Hovington, G. Beaudry, and B. Tetu Identification of PCA3 (DD3) in prostatic carcinoma by in situ hybridization Mod Pathol 20 2007 1121 1127 (Pubitemid 47609070)
8. J. Klecka, L. Holubec, and M. Pesta Differential display code 3 (DD3/PCA3) in prostate cancer diagnosis Anticancer Res 30 2010 665 670
9. PCA3 RNA analysis in urine - a new perspective for detecting prostate cancer Eur Urol 46 2004 182 187 discussion 187
10. J. Groskopf, S.M. Aubin, and I.L. Deras APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer Clin Chem 52 2006 1089 1095 (Pubitemid 43794421)
11. Y. Fradet, F. Saad, and A. Aprikian uPM3, a new molecular urine test for the detection of prostate cancer Urology 64 2004 311 315 discussion 315-6
12. L.J. Sokoll, W. Ellis, and P. Lange A multicenter evaluation of the PCA3 molecular urine test: pre-analytical effects, analytical performance, and diagnostic accuracy Clin Chim Acta 389 2008 1 6
13. D. Schilling, J. Hennenlotter, M. Munz, U. Bokeler, K.D. Sievert, and A. Stenzl Interpretation of the prostate cancer gene 3 in reference to the individual clinical background: implications for daily practice Urol Int 85 2010 159 165
14. A. Haese, A. de la Taille, and H. van Poppel Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy Eur Urol 54 2008 1081 1088
15. L.S. Marks, Y. Fradet, and I.L. Deras PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy Urology 69 2007 532 535 (Pubitemid 46428401)
16. S.B. Shappell, J. Fulmer, D. Arguello, B.S. Wright, J.R. Oppenheimer, and M.J. Putzi PCA3 urine mRNA testing for prostate carcinoma: patterns of use by community urologists and assay performance in reference laboratory setting Urology 73 2009 363 368
17. J.J. Tosoian, S. Loeb, and A. Kettermann Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program J Urol 183 2010 534 538
18. R. Wang, A.M. Chinnaiyan, R.L. Dunn, K.J. Wojno, and J.T. Wei Rational approach to implementation of prostate cancer antigen 3 into clinical care Cancer 115 2009 3879 3886
19. M. Nyberg, D. Ulmert, A. Lindgren, U. Lindstrom, P.A. Abrahamsson, and A. Bjartell PCA3 as a diagnostic marker for prostate cancer: a validation study on a Swedish patient population Scand J Urol Nephrol 44 2010 378 383
20. S.M. Aubin, J. Reid, and M.J. Sarno PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial J Urol 184 2010 1947 1952
21. F.H. Schroder, J. Hugosson, and M.J. Roobol Screening and prostate-cancer mortality in a randomized European study N Engl J Med 360 2009 1320 1328
22. G.L. Andriole, E.D. Crawford, and R.L. Grubb 3rd Mortality results from a randomized prostate-cancer screening trial N Engl J Med 360 2009 1310 1319
23. I.L. Deras, S.M. Aubin, and A. Blase PCA3: a molecular urine assay for predicting prostate biopsy outcome J Urol 179 2008 1587 1592
24. G. Ploussard, A. Haese, and H. van Poppel The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free-to-total prostate-specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies? BJU Int 106 2010 1143 1147
25. D.P. Ankerst, J. Groskopf, and J.R. Day Predicting prostate cancer risk through incorporation of prostate cancer gene 3 J Urol 180 2008 1303 1308 discussion 1308
26. M.W. Kattan Evaluating a new marker's predictive contribution Clin Cancer Res 10 2004 822 824 (Pubitemid 38198879)
27. M.W. Kattan Judging new markers by their ability to improve predictive accuracy J Natl Cancer Inst 95 2003 634 635 (Pubitemid 36603708)
28. F.K. Chun, A. de la Taille, and H. van Poppel Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram Eur Urol 56 2009 659 668
29. M. Auprich, A. Haese, and J. Walz External validation of urinary PCA3-based nomograms to individually predict prostate biopsy outcome Eur Urol 58 2010 727 732
30. S. Perdon, V. Cavadas, and G. Di Lorenzo Prostate cancer detection in the "grey area" of prostate-specific antigen below 10 ng/ml: head-to-head comparison of the updated PCPT calculator and Chun's nomogram, two risk estimators incorporating prostate cancer antigen 3 Eur Urol 59 2011 81 87
31. M.J. Roobol, F.H. Schröder, and P. van Leeuwen Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test Eur Urol 58 2010 475 481
32. J.I. Epstein, P.C. Walsh, M. Carmichael, and C.B. Brendler Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer JAMA 271 1994 368 374 (Pubitemid 24037911)
33. D.G. Bostwick, V.E. Gould, J. Qian, M. Susani, and M. Marberger Prostate cancer detected by uPM3: radical prostatectomy findings Mod Pathol 19 2006 630 633
34. H. Nakanishi, J. Groskopf, and H.A. Fritsche PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance J Urol 179 2008 1804 1809 discussion 1809-10
35. E.J. Whitman, J. Groskopf, and A. Ali PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume J Urol 180 2008 1975 1978 discussion 1978-9
36. D. Hessels, M.P. van Gils, and O. van Hooij Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer Prostate 70 2010 10 16
37. M.P. van Gils, D. Hessels, and C.A. Hulsbergen-van de Kaa Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results Prostate 68 2008 1215 1222
38. M. Auprich, F.K.-H. Chun, and J.F. Ward Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging Eur Urol 59 2011 96 105
39. G. Ploussard, X. Durand, and E. Xylinas Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance Eur Urol 59 2011 422 429
40. D.F. Gleason, and G.T. Mellinger Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging J Urol 111 1974 58 64
41. S. Larré, C. Ronsin, and J. Irani Immediate impact of ultrasound-guided prostate biopsies on PCA3 score Eur Urol 57 2010 1121 1122
42. M.P. van Gils, D. Hessels, W.P. Peelen, H. Vergunst, P.F. Mulders, and J.A. Schalken Preliminary evaluation of the effect of dutasteride on PCA3 in post-DRE urine sediments: a randomized, open-label, parallel-group pilot study Prostate 69 2009 1624 1634
43. D. Hessels, F.P. Smit, G.W. Verhaegh, J.A. Witjes, E.B. Cornel, and J.A. Schalken Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer Clin Cancer Res 13 2007 5103 5108 (Pubitemid 47502077)
44. B. Laxman, D.S. Morris, and J. Yu A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer Cancer Res 68 2008 645 649 (Pubitemid 351206738)
45. B. Ouyang, B. Bracken, B. Burke, E. Chung, J. Liang, and S.M. Ho A duplex quantitative polymerase chain reaction assay based on quantification of alpha-methylacyl-CoA racemase transcripts and prostate cancer antigen 3 in urine sediments improved diagnostic accuracy for prostate cancer J Urol 181 2009 2508 2513 discussion 2513-4
46. M. Rigau, J. Morote, and M.C. Mir PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine Prostate 70 2010 1760 1767
47. D.C. Danila, G. Heller, and G.A. Gignac Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer Clin Cancer Res 13 2007 7053 7058 (Pubitemid 350276887)
48. R.M. Väänänen, M. Rissanen, and O. Kauko Quantitative real-time RT-PCR assay for PCA3 Clin Biochem 41 2008 103 108 (Pubitemid 350216834)
49. K. Marangoni, T.G. Araujo, A.F. Neves, and L.R. Goulart The -786T > C promoter polymorphism of the NOS3 gene is associated with prostate cancer progression BMC Cancer 8 2008 273
50. G. Shaw, A.M. Price, and E. Ktori Hedgehog signalling in androgen independent prostate cancer Eur Urol 54 2008 1333 1343
51. M. Jost, J.R. Day, and R. Slaughter Molecular assays for the detection of prostate tumor derived nucleic acids in peripheral blood Mol Cancer 9 2011 174
52. H.G. van der Poel, J. McCadden, and G.W. Verhaegh A novel method for the determination of basal gene expression of tissue-specific promoters: an analysis of prostate-specific promoters Cancer Gene Ther 8 2001 927 935 (Pubitemid 33140311)
53. J.K. Fan, N. Wei, and M. Ding Targeting Gene-ViroTherapy for prostate cancer by DD3-driven oncolytic virus-harboring interleukin-24 gene Int J Cancer 127 2010 707 717
54. A. Heidenreich, J. Bellmunt, and M. Bolla EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease Eur Urol 59 2011 61 71
55. M. Remzi, A. Haese, and H. van Poppel Follow-up of men with an elevated PCA3 score and a negative biopsy: does an elevated PCA3 score indeed predict the presence of prostate cancer? BJU Int 106 2010 1138 1142
56. D. Hessels, and J.A. Schalken The use of PCA3 in the diagnosis of prostate cancer Nat Rev Urol 6 2009 255 261